Latest Insider Transactions at Gt Biopharma, Inc. (GTBP)
This section provides a real-time view of insider transactions for Gt Biopharma, Inc. (GTBP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GT Biopharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GT Biopharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 11
2023
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+18.94%
|
$0
$0.29 P/Share
|
|
Aug 11
2023
|
Manu Ohri CFO & Secretary |
BUY
Other acquisition or disposition
|
Indirect |
200,000
+40.0%
|
$0
$0.29 P/Share
|
|
Aug 11
2023
|
Manu Ohri CFO & Secretary |
SELL
Other acquisition or disposition
|
Direct |
200,000
-100.0%
|
$0
$0.29 P/Share
|
|
Aug 11
2023
|
Manu Ohri CFO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
$0
$0.29 P/Share
|
|
Apr 11
2023
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Open market or private purchase
|
Direct |
50,000
+7.08%
|
$0
$0.5 P/Share
|
|
Apr 06
2023
|
Manu Ohri CFO & Secretary |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$0
$0.5 P/Share
|
|
Jul 15
2022
|
Manu Ohri CFO & Secretary |
BUY
Other acquisition or disposition
|
Indirect |
100,000
+50.0%
|
-
|
|
Jul 15
2022
|
Manu Ohri CFO & Secretary |
SELL
Other acquisition or disposition
|
Direct |
100,000
-100.0%
|
-
|
|
Jul 15
2022
|
Manu Ohri CFO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jul 15
2022
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
278,058
+31.44%
|
-
|
|
Feb 25
2021
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Conversion of derivative security
|
Direct |
50,102
+7.07%
|
$150,306
$3.4 P/Share
|
|
Feb 16
2021
|
Gregory Berk Pres. of R&D, CMO |
BUY
Grant, award, or other acquisition
|
Direct |
278,058
+50.0%
|
-
|
|
Feb 16
2021
|
Michael Martin Breen Executive Chairman/Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
278,058
+50.0%
|
-
|
|
Feb 16
2021
|
Bruce Wendel Director |
BUY
Grant, award, or other acquisition
|
Direct |
347,572
+49.64%
|
-
|
|
Dec 22
2020
|
Bruce Wendel Director |
BUY
Open market or private purchase
|
Direct |
1,815
+15.41%
|
$14,520
$8.8 P/Share
|
|
Dec 22
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
47,978
-1.27%
|
$0
$0.4 P/Share
|
|
Dec 21
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
135,722
-1.17%
|
$0
$0.32 P/Share
|
|
Dec 18
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
50,000
-1.26%
|
$0
$0.3 P/Share
|
|
Dec 17
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
100,000
-1.24%
|
$0
$0.31 P/Share
|
|
Dec 16
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
50,000
-1.22%
|
$0
$0.3 P/Share
|
|
Dec 15
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
150,000
-1.19%
|
$0
$0.31 P/Share
|
|
Dec 14
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
146,300
-1.12%
|
$0
$0.29 P/Share
|
|
Dec 11
2020
|
Steven W Weldon |
SELL
Open market or private sale
|
Direct |
100,000
-1.12%
|
$0
$0.26 P/Share
|
|
Nov 16
2020
|
Bruce Wendel Director |
BUY
Open market or private purchase
|
Direct |
3,268
+50.0%
|
$9,804
$3.14 P/Share
|